AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06075043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Oral administration of AND017 capsules three times per week
Study NCT05196477 — intervention group
Intervention type: DRUG
Intervention: Olokizumab
Description: The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
Study NCT05196477 — intervention group
Intervention type: DRUG
Intervention: Standard therapy
Description: Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
Study NCT05143606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-printed airway simulator
Description: Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
Study NCT05143606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality software, AirwayEx
Description: Two self-directed training on AirwayEx. With additional training as necessary.
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 medium dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 medium dose slow Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 high dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-102 low dose fast Period 1 and Period 2
Description: GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone solution as intramuscular injection Period 1 and Period 2
Description: reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
Study NCT05531890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Solution Period 1 and Period 2
Description: Comparator product 0.1 mg/kg betamethasone oral drops solution
Study NCT05553223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microdoses of activity
Description: Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
Study NCT05580497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Wearable Robotic Knee System
Description: Power assistance will be provided from the motor to the knee joint
Study NCT05549167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
Study NCT05277077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
Study NCT05277077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
Study NCT04758052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of placement
Description: Simultaneous placement of tracheostomy and gastrostomy
Study NCT04799847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
Study NCT04731350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial extracorporeal shock wave
Description: Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
Study NCT04731350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iontophoresis
Description: Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
Study NCT04731350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: strengthening exercise
Study NCT05529732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Mobile Application Patient Education for Patients with Thyroidectomy
Description: Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery.
Study NCT04965428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear-focused Self-Compassion Therapy
Description: The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
Study NCT05890300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of an occupational passive back-exoskeleton
Description: The experimental group will use an occupational passive back-exoskeleton (ShoulderX V3, Ottobock bionics) for a period of 24 weeks during working hours. The exoskeleton is designed to reduce the load of the lower back during manual materials handling. The first four weeks will serve as a familiarization period, where the workers will slowly progress in hours of exoskeleton-use, while they in the remaining twenty weeks will be free to use the exoskeleton as much as they like, with a minimum limit of 18 hours per week. The control group will carry on their normal work without any changes.
Study NCT04731350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: strengthening exercise
Study NCT05391945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
Study NCT06288542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group d
Description: this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
Study NCT06288542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group R
Description: this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
Study NCT05050422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)
Description: control/study group
Study NCT05050422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)
Description: control/study group
Study NCT05438134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.
Study NCT05438134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART-3RP Group Intervention
Description: Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice.
Study NCT04762303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedReviewRx
Description: During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
Study NCT05247697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
Description: Mirtazapine 7,5 mg capsule
Study NCT05247697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet once daily at bedtime
Description: Matching placebo
Study NCT05302297 — intervention group
Intervention type: DRUG
Intervention: Cemiplimab
Description: Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
Study NCT05260593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin B12 phonophoresis
Description: Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
Study NCT05260593 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin B12 phonophoresis
Description: Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
Study NCT05260593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist splint
Description: Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
Study NCT05260593 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wrist splint
Description: Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
Study NCT05260593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tendon and nerve gliding exercises
Description: During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
Study NCT05260593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tendon and nerve gliding exercises
Description: During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
Study NCT05743647 — intervention group
Intervention type: DEVICE
Intervention: Observation (OBS)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement.
Study NCT05743647 — intervention group
Intervention type: DEVICE
Intervention: Observation and imagination (OBS-IM)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it.
Study NCT05729204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic seawater solution
Description: Nasal irrigations with hypertonic seawater solution
Study NCT06140394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diode laser
Description: low level diode therapy
Study NCT06140394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diode laser
Description: low level diode therapy
Study NCT06140394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical scaling
Description: non surgical scaling using ultrasonic
Study NCT06140394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non surgical scaling
Description: non surgical scaling using ultrasonic
Study NCT05743647 — intervention group
Intervention type: DEVICE
Intervention: Observation and realization (OBS-REAL)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it
Study NCT06321497 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal carbon dioxide removal
Description: Low flow extracorporeal carbon dioxide removal with PrismaLung+
Study NCT05046106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC1501
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Study NCT05046106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caramel, chocolate brown, flavor (E_1982648), dextrin
Study NCT04966559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Study NCT04966559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naldemedine 0.2 MG Oral Tablet
Description: Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Study NCT05928663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double surgical gloves
Description: In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
Study NCT05928663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: single surgical gloves
Description: MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
Study NCT03729713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation
Description: 6 week course of cognitive rehabilitation focused on attention, learning, and memory
Study NCT03729713 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham placebo
Description: an alternative home-based computer program not designed for cognitive remediation but of the same duration
Study NCT04805957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
Study NCT06209762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
Study NCT06209762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
Study NCT06542406 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endotracheal intubation
Description: The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
Study NCT04749407 — intervention group
Intervention type: GENETIC
Intervention: biomarker detection
Description: PBMC and ctDNA analysis
Study NCT04670770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug - SHR1459
Description: Oral Tablets taken once daily for 52 weeks
Study NCT05176691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-760
Description: Administered orally QD for 28-day cycles
Study NCT05259618 — intervention group
Intervention type: OTHER
Intervention: Tasso+ SST
Description: alternative site blood sample collection.
Study NCT04283227 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-200
Description: All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
Study NCT05161741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Human rDNA Insulin (Insuget, local brand of Getz Pharma)
Study NCT05026489 — intervention group
Intervention type: GENETIC
Intervention: G6PD gene deficiency
Description: we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
Study NCT05568368 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT06239259 — intervention group
Intervention type: OTHER
Intervention: Questionare As described in Secondary Outcomes
Description: All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
Study NCT05276778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic Retinopathy Screening
Description: Screenings are performed in the diabetes consultation in general practice
Study NCT06282640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
Study NCT06486142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib/Dacomitinib
Description: Second-generation EGFR-inhibitors
Study NCT06486142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Third-generation EGFR-inhibitor